Pyloric or Pseudopyloric Metaplasia of the Corpus Mucosa in Autoimmune Gastritis (PM_in_AIG)
To Validate That Pyloric or Pseudopyloric Metaplasia of the Corpus Mucosa is a Specific Pathological Feature of Autoimmune Gastritis
Sponsor: National Cheng-Kung University Hospital
A observational or N/A phase clinical study on Anemia, Pernicious and Autoimmune Diseases, this trial is ongoing. The trial is conducted by National Cheng-Kung University Hospital and has accumulated 7 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Dec 2025 — Present [monthly]
Unknown
-
Nov 2025 — Dec 2025 [monthly]
Unknown
Status: Enrolling By Invitation → Unknown
-
Sep 2025 — Nov 2025 [monthly]
Enrolling By Invitation
-
Sep 2024 — Sep 2025 [monthly]
Enrolling By Invitation
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation
▶ Show 2 earlier versions
-
Nov 2023 — Jul 2024 [monthly]
Enrolling By Invitation
-
Mar 2022 — Nov 2023 [monthly]
Enrolling By Invitation
First recorded
Jan 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cheng-Kung University Hospital
- Tainan Hospital, Ministry of Health and Welfare
For direct contact, visit the study record on ClinicalTrials.gov .